Adapting to darkness

Article

Scientists studying a neural retina in a salamander have found Müller cells in the promoted cone-specific pigment regeneration and dark adaptation that are independent of the pigment epithelium.

Scientists studying a neural retina in a salamander found Müller cells in the promoted cone-specific pigment regeneration and dark adaptation that are independent of the pigment epithelium.

Similar to glial cells in the brain Müller cells in the retina support and interact with photoreceptors. The researchers removed the pigment epithelium layer preventing the pigment molecules from recycling using a known pathway. They then exposed the retina to bright light then darkness and found that the cones continued to function, making it clear that a second pathway was being employed.

Their discovery will enhance our understanding of human diseases affecting the retina, including age-related macular degeneration (AMD). The researchers results are published in the March issue of Nature Neuroscience.

Principal investigator Vladimir J. Kefalov, PhD, assistant professor of ophthalmology and visual sciences at Washington University School of Medicine believes that there are major implications for AMD, where cone cells malfunction over time. This would take the form of targeting the pathway, revving up its activity and supplementing or rescuing the function of the cones.

Before that happens, he says it will be important to figure out exactly how the Müller cells are interacting with photoreceptors. Although these studies confirmed the existence of the second photoreceptor pathway, they didn't reveal how it works. Kefalov's laboratory has recently received a five-year, $1.9 million National Eye Institute grant to study how this newly identified visual pathway functions in the retina.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.